Therefore, anti-VEGFR antibodies and VEGF inhibitors are expected to block angiogenesis, thereby reducing tumor blood flow and nutrient supply, increasing vascular permeability, and facilitating drug penetration into the tumor. The gene discussed is VEGFA; the disease is neoplasm.